What comes after a CDK4/6 inhibitor stops working?

For people with hormone receptor positive, HER2-negative metastatic breast cancer, first-line treatment is usually hormone therapy with a CDK4/6 inhibitor such as ribociclib, palbociclib or abemaciclib. When scans show the cancer is growing on this treatment, there are several options, and the choice depends a great deal on testing. Doctors usually recommend genetic testing of the cancer, either from a new biopsy or a blood test called a liquid biopsy, to look for changes in genes such as ESR1, PIK3CA, AKT1, PTEN and inherited BRCA genes. Each result can point to a specific treatment. In general terms, options include switching to a different hormone therapy such as fulvestrant; an oral SERD such as elacestrant for cancers with an ESR1 mutation; hormone therapy combined with a targeted tablet such as alpelisib or capivasertib when PIK3CA, AKT1 or PTEN changes are present; everolimus with exemestane; PARP inhibitors such as olaparib or talazoparib for people with inherited BRCA mutations; and, when hormone treatments are no longer effective, chemotherapy or antibody-drug conjugates such as trastuzumab deruxtecan for HER2-low cancer or sacituzumab govitecan. Continuing a CDK4/6 inhibitor with a different hormone partner is also being studied.

How fast the cancer is growing matters

If cancer grew within a short time on the CDK4/6 inhibitor, or organs are under strain, chemotherapy or an antibody-drug conjugate may be preferred sooner.

Testing is a key step

Genetic results can take a few weeks, so ask early whether testing should be done at the first sign of progression.

Availability varies

Not every medicine mentioned here is approved, affordable or easy to access in every country. Your oncologist can explain what is realistic.

Progression on a CDK4/6 inhibitor is an important turning point, but it is not the end of effective options. Understanding the realities helps with planning.

Later treatments often work for shorter periods

On average, second-line hormone-based treatments control cancer for a shorter time than first-line treatment, though some people respond well for longer.

Side effects differ between options

Targeted tablets can raise blood sugar, cause rash, mouth sores or loose motions. Everolimus can cause mouth sores and lung inflammation. Antibody-drug conjugates can cause nausea, hair loss and low blood counts.

Access and cost are real barriers

Some newer medicines are expensive or not yet available everywhere. Clinical trials and access programmes may help.

Evidence continues to change

New trials are regularly reported, so the best sequence may change over time.

What this page cannot tell you

It cannot choose your treatment. Ask your oncologist which option suits you.

Choosing the next treatment is a shared decision that balances evidence, testing, side effects and your life.

Timing of progression

Cancer that was controlled for a long time on the CDK4/6 inhibitor is more likely to respond to further hormone-based treatment.

Your health and priorities

Other conditions, such as diabetes, and your preference for tablets or drips, clinic visits and side effects all matter.

Clinical trials

Ask whether a trial is available, as this setting is an active area of research.

Second opinions

A second opinion can be helpful before a major change in treatment.

Hearing that first-line treatment has stopped working often brings fear for the whole family, even though further options usually exist.

Help gather information

Collect previous reports, test results and a list of medicines so the team can plan quickly.

Share decisions

Attend appointments when invited, take notes and help weigh options, while respecting the person's own priorities.